David Kaslow, FDA's incoming director of CBER's Office of Vaccines Research and Review
FDA hires new vaccine director, a year after two senior leaders quit in protest
After almost exactly a year since the FDA’s top two vaccine leaders left in protest over boosters-for-all, the FDA has now named former Merck VP David Kaslow as its new director of CBER’s Office of Vaccines Research and Review.
Kaslow will replace acting director Peter Marks (who is also head of CBER) after he had to step in to replace Marion Gruber, who resigned suddenly alongside her deputy Philip Krause in late 2021 after they disagreed with the agency’s booster strategy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
